| Drug Name: | Sorivudine (77181-69-2) |
|---|---|
| PubChem ID: | 5282192 |
| SMILES: | C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br |
| InchiKey: | GCQYYIHYQMVWLT-HQNLTJAPSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 349.137 |
| LogP | : | -1.4863 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 124.78 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Fluorouracil (51-21-8) | Anorexia | Synergistic | Sorivudine appears to be converted in the gut into a metabolite (BVU or bromovinyluracil) that is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of fluorouracil | Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|